IBRX - Company ID 0001326110
ImmunityBio, Inc. (IBRX) reported revenue of $113.29M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $113.29M | +668.3% |
| FY 2024 | $14.74M | +2270.6% |
| FY 2023 | $622.00K | +159.2% |
| FY 2022 | $240.00K | -74.3% |
| FY 2021 | $934.00K | +54.4% |
| FY 2020 | $605.00K | -72.5% |
| FY 2019 | $2.20M | +4585.1% |
| FY 2018 | $47.00K | +4.4% |
| FY 2017 |
ImmunityBio, Inc. (IBRX) reported revenue of $113.29M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, ImmunityBio, Inc.'s revenue grew from $600.00K to $113.29M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $45.00K |
| +2.3% |
| FY 2016 | $44.00K | -81.4% |
| FY 2015 | $236.00K | -63.2% |
| FY 2014 | $641.00K | +6.8% |
| FY 2013 | $600.00K | - |